Kane Biotech Inc. received approval from the University of Miami Health System’s Internal Review Board to begin a clinical study of its DispersinB® Acne Cleanser for mild to moderate acne. The study, expected to start mid-2025, will involve up to 24 participants at the University of Miami Miller School of Medicine, a recognized leader in dermatology. The split-face study will evaluate the efficacy and tolerability of the cleanser.
This clinical trial is a crucial step for Kane Biotech as it seeks to validate the effectiveness of its DispersinB® technology in a real-world setting. Positive results could significantly bolster the company’s credibility and market potential, particularly within the competitive acne treatment landscape. Demonstrating efficacy through a rigorous clinical study conducted by a reputable institution is essential for attracting potential partners, investors, and ultimately, consumers. It offers an opportunity for Kane Biotech to differentiate its product within a market saturated with various acne solutions.
The study focuses on mild to moderate acne, a large segment of the acne-affected population. It is designed as a split-face trial, allowing researchers to directly compare the effects of the DispersinB® cleanser against a control on the same individual, enhancing the reliability of the results. Collaborating with the University of Miami provides access to expertise and resources, lending further weight to the study’s findings.
This trial represents a significant advancement in Kane Biotech’s efforts to commercialize its DispersinB® technology for acne treatment. Successful results could pave the way for broader market adoption, potentially positioning DispersinB® as a valuable new tool in the fight against acne. The data generated will be key for future product development, marketing strategies, and establishing the cleanser’s efficacy and safety profile. This could lead to significant growth opportunities for Kane Biotech and provide a novel solution for acne sufferers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
